What is Dyax Retained Earnings?
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Dyax's retained earnings for the quarter that ended in Sep. 2015 was $-573.22 Mil.
Dyax's quarterly retained earnings
declined
from Mar. 2015 ($-553.11 Mil) to Jun. 2015 ($-561.52 Mil) and
declined
from Jun. 2015 ($-561.52 Mil) to Sep. 2015 ($-573.22 Mil).
Dyax's annual retained earnings
declined
from Dec. 2012 ($-506.19 Mil) to Dec. 2013 ($-533.96 Mil) and
declined
from Dec. 2013 ($-533.96 Mil) to Dec. 2014 ($-545.84 Mil).
Dyax Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Dyax (NAS:DYAX) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Dyax (DYAX) Business Description
Traded in Other Exchanges
N/A
Address
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
| David J Mclachlan |
other: Former director |
ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
| Gustav Christensen |
officer: CEO and President, other: Former director |
DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Todd Bazemore |
officer: EVP & Chief Commercial Officer |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Thomas L Kempner |
other: Former director |
C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004 |
| Abbie Celniker |
other: Former director |
C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142 |
| Marc D Kozin |
other: Former director |
|
| Andrew D. Ashe |
officer: General Counsel & EVP |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Ron Cohen |
other: Former director |
C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
| Mary Ann Gray |
other: Former director |
201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
| George V Migausky |
officer: EVP & Chief Financial Officer |
C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Paolo Pucci |
other: Former director |
C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
| Burt A Adelman |
officer: CMO & EVP, R&D |
DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Ivana Magovcevic-liebisch |
officer: EVP; Chief Operating Officer |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Susan B Bayh |
director |
WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
| Stephen S Galliker |
officer: EVP and CFO |
300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DYAX has been successfully added to your 